Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Allergy Thera. (AGY) Share News

DIRECTOR DEALINGS: Allergy Therapeutics Executives Acquire Shares

25th Apr 2014 08:44

LONDON (Alliance News) - Allergy Therapeutics PLC said Friday that Chief Executive Manuel Llobet and Finance Director Ian Postlewaite acquired shares at nil cost under the company's long term share incentive plan on Thursday, as follows: <table class="aj" style="width: 417px; he Read More

Allergy Therapeutics Extends Term Of Convertible Loan

17th Apr 2014 10:44

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it had extended the term of its GBP4.04 million convertible loan with CFR International SpA. The maturity of the loan has been extended to September 30 from April 20, all other terms of the loan are unchanged. Shares Read More

UK BROKER RATINGS: Jefferies Raises REIT Price Targets

1st Apr 2014 09:11

LONDON (Alliance News) - The following UK shares received analyst recommendations Tuesday morning: ---------- FTSE 100 ---------- GOLDMAN RAISES INTL AIRLINES GROUP (IAG) PRICE TARGET TO 430 (420) PENCE - 'NEUTRAL' ---------- BARCLAYS CUTS PRUDEN Read More

UK MIDDAY BRIEFING: Centamin Soars As Production Beats Expectations

24th Mar 2014 13:15

LONDON (Alliance News) - Metals and minerals producer Centamin is leading the FTSE 250 index Monday despite reporting a hit to pretax profit in 2013, due to a large exceptional cost, but a significant increase in revenue and production. Centamin said pretax profit f Read More

UK WINNERS & LOSERS: Barratt Falls On Return To FTSE 100, Downgrade

24th Mar 2014 12:15

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday. ------- FTSE 100 - LOSERS Barratt Developments, down 2.1%. Following the quarterly FTSE review on Ma Read More

Allergy Therapeutics Profit Rises On Increased Market Share In Europe

24th Mar 2014 11:11

LONDON (Alliance News) - Speciality pharmaceutical company Allergy Therapeutics PLC Monday posted a rise in pretax profit as it increased its market share in European markets and launched new products in the half-year ended December 31, 2013. Allergy Therapeutic posted a pretax profit of GB Read More

UK Earnings, Trading Statements Calendar - Week Ahead

24th Mar 2014 06:42

UK Earnings, Trading Statements Calendar - Week Ahead

21st Mar 2014 16:11

UK Earnings, Trading Statements Calendar - Week Ahead

21st Mar 2014 06:13

UK Earnings, Trading Statements Calendar - Week Ahead

20th Mar 2014 16:02

UK Earnings, Trading Statements Calendar - Week Ahead

20th Mar 2014 06:33

UK Earnings, Trading Statements Calendar - Week Ahead

19th Mar 2014 16:42

UK Earnings, Trading Statements Calendar - Week Ahead

19th Mar 2014 06:15

UK Earnings, Trading Statements Calendar - Week Ahead

18th Mar 2014 15:54

UK Earnings, Trading Statements Calendar - Week Ahead

18th Mar 2014 06:31

UK Earnings, Trading Statements Calendar - Week Ahead

17th Mar 2014 15:51

Allergy Therapeutics Reports Profits, Revenues For Year To End-September

12th Mar 2014 11:33

LONDON (Alliance News) - Allergy Therapeutics PLC Wednesday reported revenues of GBP40.5 million and a profit of GBP890,000 for the 12 months to September 30, 2013. The company's financial year runs until the end of June, but it has provided additional figures for the year to end-September Read More

Allergy Therapeutics' Hay Fever CTA Approved By Health Canada

19th Feb 2014 09:12

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday that the Canadian health authority has approved its proposal to submit a full clinical trial application for an efficacy study for Pollinex Quattro Grass MATA MPL (0.5ml). The speciality pharma firm said its proposal for a new Read More

Allergy Therapeutics Says Positive Ragweed Allergy Treatment Published

27th Jan 2014 09:57

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday that results from its Phase IIb clinical trial of its Pollinex Quattro ragweed allergy treatment have been published in the Journal of Allergy and Clinical Immunology. The trial showed that the treatment was safe and effective in Read More

Allergy Therapeutics Revenues Up 16%, Appoints New R&D Director

20th Nov 2013 10:05

FTSE 100 Latest

Value9,309.20

Change21.06